ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Coronavirus

Moderna says COVID-19 vaccine immunity lasts at least a year

Company expects to deliver between 600m and 1bn doses in 2021

A health care worker prepares a dose of the Moderna COVID-19 vaccine at Queens Police Academy in New York on Jan. 11.   © Reuters

Immunity from Moderna Inc's COVID-19 vaccine should last at least a year, the company said on Monday at the J.P. Morgan Healthcare conference.

The drugmaker said it was confident that the messenger RNA (mRNA) technology it used was well suited to deploy a vaccine based on the new variant of the coronavirus which has emerged in a handful of countries.

The company's vaccine, mRNA-1273, uses synthetic mRNA to mimic the surface of the coronavirus and teach the immune system to recognize and neutralize it.

Moderna said in December it would run tests to confirm the vaccine's activity against any strain.

The company said on Monday it expects to deliver between 600 million doses and 1 billion doses of its vaccine in 2021 and forecast vaccine-related sales of $11.7 billion for the year, based on advance purchase agreements signed with governments.

"The team feels very comfortable with the track record we have now ... that we are on track to deliver at least 600 million doses," Chief Executive Officer Stephane Bancel said. 

(Reuters)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more